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Objectives: This study was performed to determine whether there is deterioration in renal function during follow-up in
patients who have undergone endovascular aneurysm repair (EVAR), as recommended by the device manufacturers; to
determine whether suprarenal fixation correlates with impairment of renal function; and to explore the potential
implication of life-long surveillance of renal function with contrast-enhanced computed tomography.
Methods: One hundred forty-six consecutive patients underwent EVAR at our institution. Data from 113 of these patients
who were free from preoperative renal insufficiency or postoperative renal disease were analyzed. Fifty-three patients
received infrarenal (IR) fixation devices, and 60 patients received suprarenal (SR) fixation devices. All SR fixation devices
were placed under investigational device exemption protocols. The average follow-up was 688 days. Sixty-five consecutive
patients who had undergone open repair of an abdominal aortic aneurysm (AAA) served as the control group.
Results: Preoperative creatinine concentration, intraoperative blood loss, contrast volume, and number of contrast-
enhanced procedures were not significantly different between the IR and SR groups. Two renal artery occlusions (1 SR,
1 IR; P  NS) were identified, and 8 renal infarcts (5 SR, 3 IR; P  NS). There was an increase in mean creatinine
concentration in the open AAA, IR, and SR fixation groups at each time point in the analysis. Mean elevation in creatinine
concentration at 12, 24, and 36 months was 0.10, 0.10, and 0.04 mg/dL, respectively, for open AAA repair; 0.20, 0.21,
and 0.28 mg/dL for IR fixation; and 0.15, 0.21, and 0.12 mg/dL for SR fixation. At life table analysis, renal impairment
at 36 months was seen in 36%  9% of patients in the IR group, 25%  % of patients in the SR group, and 19%  6% of
patients in the open AAA group (P  .04 for IR fixation vs open AAA repair).
Conclusions: A decrease in kidney function is seen after EVAR, regardless of fixation level, that is independent of renal
disease and renal arterial occlusion. In patients with normal renal function the site of proximal fixation does not affect
postoperative creatinine concentration. The decrease in renal function is likely related to the repetitive administration of
contrast agent. (J Vasc Surg 2004;39:804-10.)Endovascular aneurysm repair (EVAR) has become an
accepted method in appropriate candidates with an infrare-
nal abdominal aortic aneurysm (AAA). As many as two
thirds of patients with AAA can now be offered EVAR.1
The initial US Food and Drug Administration (FDA)–
approved devices both used infrarenal fixation at the prox-
imal attachment site. As part of the approval process, the
FDA requires patients to be followed up at regular intervals
with contrast-enhanced computed tomography (CT) as
though they were involved in the investigational device
exemption protocols. Recently Cook Inc (Bloomington,
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doi:10.1016/j.jvs.2003.11.043804Ind) received approval for the Zenith graft, a device that
uses suprarenal fixation. Medtronic/AVE (Santa Rosa,
Calif) is in the final stages of submitting data to the FDA
regarding the Talent graft, another suprarenal device. The
combination of suprarenal fixation and repetitive intrave-
nous contrast agent administration could create additive
deleterious effects on the kidneys.
The physiologic effects of suprarenal fixation on long-
term renal function remain entirely unknown. Several re-
ports have indicated an acceptable short-term effect of
suprarenal fixation on kidney function.2-8 The purposes of
this report were to determine whether there is deterioration
over the longer term in renal function in patients who have
undergone EVAR, to determine whether suprarenal fixa-
tion correlates with impairment in renal function, and to
explore the potential implication of life-long CT surveil-
lance on renal function in patients who undergo follow-up
imaging protocols as recommended by the device manufac-
turers.
METHODS
From August 1997 through December 2002, 158
patients underwent endovascular aneurysm procedures at
our institution. Data for 12 patients with ruptured, tho-
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analysis. From these 146 patients, 23 patients with preop-
erative chronic renal failure (serum creatinine concentra-
tion, 1.5 mg/dL), 8 patients with postoperative renal
infarct, and 2 patients with renal artery occlusion were
excluded from the analysis. The intent of our study design
was to examine only those patients with no identifiable
renal disease, to eliminate preexisting renal disease as a
cause of postoperative renal dysfunction. This group of 113
patients without preoperative or postoperative renal com-
promise formed the core group of the study.
CT scans were reviewed to determine the actual site of
proximal endograft fixation and the presence of renal in-
farcts. Fixation was classified as suprarenal (SR) if metallic
material extended to or above the level of the renal arteries,
and as infrarenal (IR) if the metallic material was below the
level of the renal arteries. Fixation was classified as IR in 53
patients, and as SR in 60 patients. The study schema is
shown in Fig 1.
Five different endografts were used during the study:
Vanguard (Meadox/Boston Scientific, Natick, Mass), Tal-
ent (World Medical/Medtronic/AVE, Santa Rosa, Calif),
Zenith (Cook), AneuRx (Medtronic/AVE), and Excluder
(W. L. Gore, Flagstaff, Ariz). The institutional review
board at the University of Rochester approved all study
protocols and consent forms. All patients gave informed
consent before the procedures, and the University of Roch-
ester received commercial funding for patients enrolled in
Phase I, II, and III studies. Patients were selected for
endografts on the basis of widely available anatomic criteria
specific for each endograft.
Serum creatinine concentration measurements from 6,
3, and 1 month before EVAR (when available) were aver-
aged to form a baseline creatinine concentration. All three
measurements were available for 45% of patients; two mea-
surements were available for 39% of patients; and only one
measurement was available for 16% of patients. All patients
who received endografts were followed up postoperatively
with physical examination, abdominal x-ray studies, helical
abdominal or pelvic CT, and serum creatinine measure-
ments at 1, 6, and every 12 months after the procedure.
Postoperative creatinine concentrations were compared
with baseline to establish changes (increase or a decrease) in
creatinine concentration. Creatinine concentration in a
randomly selected group of 65 patients who underwent
open repair of AAA at our institution from 1998 through
2002 was similarly tabulated and used as a contemporary
comparison with patients undergoing EVAR. Patients un-
derwent open repair when they were deemed anatomically
unsuitable for the endografts available for consideration.
We did not eliminate patients with renal infarction and
renal artery occlusion from the open AAA group, because
postoperative CT scans were not routinely obtained in this
group of patients.
Data analysis. Preoperative risk factors were catego-
rized as described by reporting standards of the Society for
Vascular Surgery and the American Association for Vascular
Surgery comorbidity grading system.9 Data were compiledaccording to recently published reporting standards for
endovascular aneurysm repair.10 Statistical comparisons for
categorical data were performed with the Fisher exact test
for categorical data. Continuous data were evaluated with
the Student t test. The Kaplan-Meier method was used to
analyze freedom from renal insufficiency. Renal insuffi-
ciency was defined as an increase in serum creatinine con-
centration of 20% or more and a level of 1.5 mg/dL or
greater. All statistical analysis was performed with JMP
statistical software (version 5.01a; SAS Institute, Cary,
NC). All tests performed were two-tailed analyses. Statisti-
cal significance at P  .05.
RESULTS
Demographic data for patients (before exclusion) with
IR, SR, and open AAA repair are summarized in Table I. A
larger percentage of men was seen in the SR group (93%)
compared with the IR group (72%) and open AAA group
(76%). Baseline creatinine concentrations were similar be-
tween the three groups (1.04 mg/dL IR, 1.05 mg/dL SR,
and 1.02 mg/dL open AAA). All other risk factors studied
revealed no difference between the three groups.
Pre-procedure renal data (before patient exclusion) and
post-procedure renal data for patients who received en-
dografts are shown in Table II. No significant differences
were seen in the number of patients for SR versus IR
fixation with regard to preoperative chronic renal failure,
end-stage renal disease, absent kidney, or preoperative renal
artery stenosis. No patients had received preoperative kid-
ney transplants. Procedure time, estimated blood loss, con-
trast volume, and patient weight were not statistically dif-
ferent between the IR and SR fixation groups.
The progressive change in serum creatinine concentra-
tion after open AAA repair is shown in Fig 2, A. Significant
increases (as compared with a change of 0 mg/dL) were
seen at 6, 12, and 18 months after open AAA repair. A
trend line of the mean changes revealed a stable change of
Fig 1. Study overview. EVAR, Endovascular aneurysm repair; IR,
infrarenal fixation; SR, suprarenal fixation.
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IR and SR EVAR fixation are shown in Fig 2, B. Significant
increases (P  .05 when comparing the mean change with
0 mg/dL) were seen at 3, 6, 18, 24, and 36 months for IR
fixation, and at 6, 12, 18, 24, and 36 months for SR
fixation. When trend lines are added, however, there is an
increasing creatinine change over time for both IR and SR
fixation. The trend is more pronounced for IR fixation, and
differs from the flat trend seen with open AAA repair. A
direct comparison of creatinine concentration change be-
tween IR fixation and SR fixation (Fig 3) showed lower
creatinine concentration change in the SR fixation group at
six of seven time points; however, no single comparison was
statistically significant.
Freedom from renal impairment (1-36 months) was
assessed with the Kaplan-Meier method for open AAA, SR
fixation, and IR fixation (Fig 4). Renal impairment was seen
least often in the open AAA repair group, followed by the
SR fixation group, and most often in the IR fixation group.
Comparison of the open AAA group against all EVAR (IR
plus SR; Fig 5) revealed decreased freedom from renal
Table I. Preoperative data, before patient exclusion
IR (n  64)
n %
Age (y) 73
Gender (% male) 72
AAA diameter (cm) 5.6
Diabetes 10 16
Tobacco use 17 27
Hypertension 38 59
Hyperlipidemia 21 33
Myocardial infarction (6 mo) 12 19
Baseline creatinine (mg/dL) 1.04
IR, Infrarenal fixation; SR, suprarenal fixation; O, open AAA repair; AAA,
Table II. Preoperative, postoperative, and intraoperative r
patients indicated by bold type. CRF  chronic renal failu
IR (n 
n
Preoperative
CRF, baseline Cr  1.5 mg/dL* 7
ESRD; preoperative hemodialysis 0
Kidney transplant, preoperatively 0
Absent kidney, preoperatively 0
Renal artery stenosis or stent 5
Postoperative
Renal infarct* 3
Renal artery occlusion* 1
Intraoperative factors
Weight (kg) 82
Contrast volume (mL) 133
Estimated blood loss (mL) 575
Procedure time (min) 194
CRF, Chronic renal failure; Cr, creatinine concentration; ESRD, end-stage
*Excluded patients.impairment in the EVAR group at all time points, but this
result was not statistically significant (P  .10). A direct
comparison of SR and IR fixation revealed less renal impair-
ment in the SR group, but this result was not statistically
significant. However, when the open AAA group was com-
pared with the EVAR group with IR fixation, there was a
statistically significant (P  .04) decrease in freedom from
renal impairment with IR fixation. This difference was not
apparent when the patients with SR fixation were compared
with the open group.
DISCUSSION
This study evaluated renal function in the subset of our
EVAR patient population who were free of preoperative
renal failure and postoperative renal events. We compared it
with a group of patients who had undergone open AAA
repair with a mean follow-up of 24 months. We found a
global decline in renal function in the patients after EVAR.
At life-table analysis, a significant decline in renal function
was seen in patients with IR fixation compared with open
AAA repair. A direct comparison of SR and IR fixation
SR (n  82) O (n  65)
Pn % n %
74 73 NS
93 76 .05
5.7 5.8 NS
12 15 9 14 NS
24 30 17 26 NS
34 43 40 62 NS
25 31 23 35 NS
15 19 19 29 NS
1.05 1.02 NS
inal aortic aneurysm; NS, not significant.
demographic data: Endograft groups only. Excluded
SRD  end stage renal disease.
SR (n  82)
P% n %
11 16 20 NS
0 0 0 NS
0 0 0 NS
0 1 1 NS
8 5 6 NS
5 5 6 NS
2 1 1 NS
78 NS
151 NS
379 NS
198 NS
disease.abdomenal
re. E
64)
renal
t (das
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patients with SR fixation, but this difference was not statis-
tically significant.
Most reports documenting renal function after SR have
been small series documenting minimal change in creati-
nine concentration and limited renal artery emboli or oc-
clusions. Two studies are available to date that compare SR
and IR fixation. Lau et al11 studied 57 patients with IR
fixation and 32 patients with SR fixation. At a mean fol-
low-up of 12 months they observed no significant differ-
ence in serum creatinine concentration between SR and IR
fixation groups 6 and 12 months after EVAR. Kramer et al7
compared the incidence of renal infarction in SR versus IR
fixation, and concluded that renal infarctions do not appear
to be associated with SR endograft fixation. In total, it
appears that SR fixation is safe in the short to intermediate
term.
The true long-term effect of crossing the renal artery
ostia with endovascular stents remains unknown. Birch et
al12 crossed the renal artery ostia in 24 pigs with Wallstents,
Palmaz stents, and Memotherm stents. After 6 to 15 weeks,
histologic examination revealed an organized collagen ma-
trix with endothelial cells covering the struts in contact with
the aorta. This matrix did not involve the renal artery ostia
Fig 2. A, Time after EVAR vs mean creatinine concen
open repair of abdominal aortic aneurysm. B, Mean cre
(solid triangle) and lower (solid line) 95% confidence lim
abdominal aortic aneurysm is superimposed onto the plocrossed by the Wallstents, but in 12 of 13 Memotherm
stents a disorganized cellular matrix caused partial renal
occlusion. Lawrence et al13 found that placement of Giant-
n change for concurrent group of patients undergoing
e concentration change at indicated times, with upper
r comparison, trend line for patients with open repair of
hed line). IR, Infrarenal fixation; SR, suprarenal fixation.
Fig 3. Time after endograft vs change in serum creatinine concen-
tration, side-by-side comparison for each time point evaluated in
the series. Open bars, Infrarenal fixation; black bars, suprarenal
fixation.tratio
atinin
its. Fo
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that the stents remained uncovered and the vessels patent
up to 34 weeks after placement. The results of our study
suggest that SR fixation is at least as safe as IR fixation at 36
months after EVAR. More time or postmortem analysis will
be needed to assess the longer term consequences of bare-
metal stents crossing the renal artery ostia. It remains to be
seen whether stent placement will alter the course of ath-
erosclerosis at the renal artery origins.
Factors that could account for the decreased renal
function after EVAR include renal atheroemboli, renal
artery trauma, stent-induced stenoses, and contrast-related
nephropathy. We excluded patients with documented renal
emboli and renal artery trauma; thus contrast administra-
tion must be strongly considered as the factor contributing
to the increase in renal impairment in the EVAR group
compared with the open AAA repair group. Some series
have noted an increase in creatinine concentration after
EVAR4-6; others2,3,8 have not. It is important to note that
most series have not included a comparison with open AAA
repair, and none have removed preoperative renal failure
and postoperative embolism from the analysis. Recommen-
dations currently in place by the FDA and the device
manufacturers warrant that all patients with endografts
undergo routine intravenous contrast-enhanced CT fol-
Fig 4. Kaplan-Meier plot shows months after endovasc
impairment for open repair of abdominal aortic aneury
triangles), and infrarenal fixation (IR; solid squares). Tot
in the chart. *P  .04 for Open AAA vs IR fixation. Stan
SE  10% for all time points.low-up after EVAR. These policies have been instituted to
follow the exclusion of aneurysms to ensure long-term
freedom from rupture and death. The differences in creat-
inine concentration after EVAR, when compared with the
open AAA patient population, are likely attributable to
repetitive contrast administration. Evaluation of alternative
means of follow-up, including methods that do not use
nephrotoxic agents, are recommended.
In response to the findings noted in this study, we have
undertaken a strategy of renal preservation during and after
EVAR. Contrast studies are limited to only those deemed
essential at the time of EVAR. Carbon dioxide and gado-
linium are often used for preoperative studies. During
EVAR, wire movement above the renal arteries is moni-
tored and limited, catheters are kept out of the renal
arteries, and balloon inflation around the renal arteries is
limited to a single gentle inflation to engage the proximal
endograft. Patients with marginal renal function (creatinine
concentration, 1.0-1.5 mg/dL) after EVAR are given
N-acetylcysteine, 600 mg orally twice a day for 1 day before
and 2 days after any contrast study. Patients with creatinine
levels 1.5 mg/dL or greater do not undergo contrast CT
and are followed up with duplex ultrasound scanning.14
Ultrasound enables adequate visualization of sac size and
endoleak. Problems with ultrasound include difficult visu-
neurysm repair vs proportion of patients without renal
pen AAA; open circles), suprarenal fixation (SR; solid
mber of patients at risk in each time interval is indicated
error (SE) bars are omitted from the SR plot for clarity.ular a
sm (O
al nu
dard
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detection of small stent fractures. Non-contrast-enhanced
CT enables assessment of sac size and device migration.
There are several limitations to this study. This is an
observational study, and the true causes of the increases in
serum creatinine concentration for IR and SR fixation can
only be inferred. Second, the study is nonrandomized,
which implies that unrecognized factors that might modify
outcome have not been equally distributed between the IR
and SR groups. Numerous selection biases no doubt oc-
curred in the treatment decisions used in this study. More
women were included in the IR group, secondary to en-
dograft sheath size. However, implantation criteria for
commercially available endografts (AneuRx, Excluder) and
investigational device exemption–sponsored device trials
(Zenith, Vanguard) were followed, and true randomization
is not safely possible with the commercially available en-
dografts. Third, the use of serum creatinine concentration
as a marker for renal function has limited sensitivity, and
may frankly underestimate the true degree of renal dysfunc-
tion after endografting. However, decisions to treat are
usually made on the basis of serum creatinine concentra-
tion, so in this respect its use as a marker for overall renal
function is justified. Routine determination of urinary cre-
atinine clearance was not obtained. Fourth, the study may
Fig 5. Kaplan-Meier plot shows months after endovasc
impairment for open repair of abdominal aortic aneur
endovascular aneurysm repair (EVAR; solid diamonds). T
the chart. P  .10 for Open AAA vs EVAR.not be adequately powered to eliminate a type II statistical
error.
Patients who received endografts with preoperative
renal insufficiency and postoperative renal infarctions and
renal artery occlusion were excluded from the analysis. This
was done to examine only those patients with no identifi-
able renal disease, to eliminate preexisting renal disease as a
cause of postoperative renal dysfunction. We did not ex-
clude patients with renal infarcts and renal artery occlusions
from the open AAA group, because postoperative CT scans
were not routinely obtained in these patients.
A particular strength of this study is the use of the
Kaplan-Meier method for data analysis. Patients were con-
sidered to have renal impairment if their serum creatinine
concentration increased 20% and reached a level above 1.5
mg/dL. The use of the Kaplan-Meier method avoids bias-
ing the data toward a higher creatinine concentration
change as a result of a few high values. Patients with
clinically significant renal impairment are classified as such,
and the Kaplan-Meier curves can be compared reliably
between the subgroups in the study.
In summary, a decrease in renal function was observed
after EVAR, regardless of fixation level. This decrease was
independent of renal disease and renal artery occlusion. A
statistically significant increase in renal impairment was
neurysm repair vs proportion of patients without renal
(Open AAA; open circles) and entire population with
umber of patients at risk in each time interval is shown inular a
ysm
he n
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AAA repair. The global decrease in renal function com-
pared with the open AAA patient group is likely related
to the repetitive administration of contrast agent. Tech-
niques of renal preservation during and after EVAR are
recommended.
We thank JoAnne McNamera, RN, and Patricia Hack-
ett for their efforts in the preparation of the manuscript.
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